[Vaccines] Manuscript ID: vaccines-

1361698 - Accepted for Publication

From: Vaccines Editorial Office

vaccines@mdpi.com
To: Isam Bsisu isam_bsisu@hotmail.com
Cc: Rami Alqassieh
Rami_qaisieh@yahoo.com, Aiman Suleiman
Asuleima@bidmc.harvard.edu, Sami Abu-
Halaweh s.halaweh@ju.edu.jo, Abeer
Santarisi abeer_santarisi@yahoo.com,
Omar Shatnawi Omar.juve10@gmail.com,
Lara Shdaifat Shdaifatlara@gmail.com,
Amjed Tarifi amjed.tarifi@gmail.com,
Mohammad Al-Tamimi
mohammad.altamimi@hu.edu.jo, Abdel-
Ellah Al-Shudifat amalmufleh@hotmail.com,
Heba Alsmadi Sw006999@gmail.com,
Ahmed Al Sharqawi
sharqawiahmed@gmail.com, Hadeel
Alnawaiseh Hanabrklna@gmail.com, Yara
Anasweh Yara.anasweh@gmail.com, Farah
Abo Domaidah
farahabodomaidah@gmail.com, Haneen
Abu Jaber abujaber.haneen@gmail.com,
Mohammad Rashid Al-Zarir
rashed.zaareer@gmail.com, Vaccines
Editorial Office vaccines@mdpi.com, Ovidiu
Radu ovidiu.radu@mdpi.com
Sent: Monday, October 18, 2021, 11:12 AM

Dear Dr. Bsisu,

Congratulations on the acceptance of your

manuscript, and thank you for your
interest in submitting your work to Vaccines:
Manuscript ID: vaccines-1361698
Type of manuscript: Article
Title: Pfizer-BioNTech and Sinopharm: a
comparative study on post-vaccination
antibody titers
Authors: Rami Alqassieh, Aiman Suleiman, Sami
Abu-Halaweh, Abeer Santarisi,
Omar Shatnawi, Lara Shdaifat, Amjed Tarifi,
Mohammad Al-Tamimi, Abdel-Ellah
Al-Shudifat, Heba Alsmadi, Ahmed Al Sharqawi,
Hadeel Alnawaiseh, Yara
Anasweh, Farah Abo Domaidah, Haneen Abu
Jaber, Mohammad Rashid Al-Zarir, Isam
Bsisu *
Received: 14 August 2021
E-mails: Rami_qaisieh@yahoo.com,
Asuleima@bidmc.harvard.edu,
s.halaweh@ju.edu.jo,
abeer_santarisi@yahoo.com,
Omar.juve10@gmail.com,
Shdaifatlara@gmail.com,
amjed.tarifi@gmail.com,
mohammad.altamimi@hu.edu.jo,
amalmufleh@hotmail.com,
Sw006999@gmail.com,
sharqawiahmed@gmail.com,
Hanabrklna@gmail.com,
Yara.anasweh@gmail.com,
farahabodomaidah@gmail.com,
abujaber.haneen@gmail.com,
rashed.zaareer@gmail.com,
isam_bsisu@hotmail.com
Submitted to section: COVID-19 Vaccines and
Vaccination,
https://www.mdpi.com/journal/vaccines/sectio
ns/COVID-19_vaccines_vaccination
https://susy.mdpi.com/user/manuscripts/revie
w_info/75c6b09ad14ae1c6d36f0672d9efebe6

We will now edit and finalize your paper, which

will then be returned to you
for your approval. Within the next couple of
days, an invoice concerning the
article processing charge (APC) for publication
in this open access journal
will be sent by email from the Editorial Office in
Basel, Switzerland.

If, however, extensive English edits are required

to your manuscript, we will
need to return the paper requesting
improvements throughout.

We encourage you to set up your profile at

SciProfiles.com, MDPI’s
researcher network platform. Articles you
publish with MDPI will be linked to
your SciProfiles page, where colleagues and
peers will be able to see all of
your publications, citations, as well as other
academic contributions.

We also invite you to contribute to Encyclopedia

(https://encyclopedia.pub),
a scholarly platform providing accurate
information about the latest research
results. You can adapt parts of your paper to
provide valuable reference
information, via Encyclopedia, for others both
within the field and beyond.

Kind regards,
Ralph A. Tripp
Editor-in-Chief